NEWS

New Lung Cancer Drug-Targeted Drug Tagrisso Approved in EU

Release time:

2018-07-24 14:00

British pharmaceutical giant AstraZeneca (AstraZeneca) in6Announced in January, the European Commission (EC) Targeted anticancer drugs approvedTagrisso(The active ingredient isOsimertinib mesylate, osimertinib) as a monotherapy, first-line treatment carryingEGFRLocally advanced or metastatic NSCLC with activating mutations (NSCLC) Adult patients.

Studies have shown that,Tagrissoand standardsEGFR-TKIThe safety and tolerability are consistent with the known properties of each drug.3Grade and above adverse event rate,Tagrissomore standardEGFR-TKILow (34% vs 45%）。

Tagrissoas the third generationEGFR-TKI: Aim to overcome generation one or twoEGFR-TKIDrug resistance, including Roche/Anstei sales in the coming year20Billion US dollars of Trocquer (Tarveca), AstraZeneca's Iressa (Iressa), Boehringer Ingelheim'sGilotrif(afatinib, Afatinib).

In the United States and the European Union,Tagrissohave been separately in2015Year11month and2016Year2Approved in January, becoming the first approved listing for use byEGFR-TKILocally advanced or metastatic disease progression during or after treatmentEGFR T790Mmutation positiveNSCLCof drugs. In the Chinese market,TagrissoIn2017Year3Monthly acquisitionCFDAApproved for the same indications.T790Mmutation andTAKESAcquired drug resistance. This year4In the middle of the month,TagrissoGet the United States again.FDAApproved, single-agent first-line therapyEGFRmutation positiveNSCLC.

Related Patent Information

United States:

Patent Name

Patent Number

Application Date

Legal status

2-(2,4,5-Substituted-Anilino) Pyrimidine Compounds

US8946235

20120725

Authorization

2-(2,4,5-Substituted-Anilino) Pyrimidine Compounds

US9732058

20141219

Authorization

China:

Patent Name

Patent Number

Application Date

Legal status

2-(2,4,5-substituted aniline)Pyrimidine derivativesEGFRTuner for cancer treatment

CN103702990B

20120725

Authorization

2-(2,4,5-substituted aniline)Pyrimidine derivativesEGFRTuner for cancer treatment

CN104109161B

20120725

Authorization

supersededN;(2;methoxy;5;nitrophenyl)Pyrimidine;2;Amine compounds and their salts

CN105254616B

20120725

Authorization

superseded3-Chlorine-N-[3 -(Pyrimidine-2-amino group)Phenyl]Propionamide or a salt thereof

CN105348266B

20120725

Authorization

superseded4;methoxy;N3;(Pyrimidine;2;Base)Benzene;1,3;Diamine compounds and salts thereof

CN105175396B

20120725

Authorization

supersededN;(4;Fluorine;2;methoxy;5;nitrophenyl)Pyrimidine;2;Amine compounds and their salts

CN105198862B

20120725

Authorization

2-(2,4,5-substituted aniline)Pyrimidine derivativesEGFRTuner for cancer treatment

CN104109151B

20120725

Authorization